IPSEN, OOO
- Country
- 🇷🇺Russia
- Ownership
- -
- Established
- 1929-01-01
- Employees
- 5.7K
- Market Cap
- $9.8B
- Website
- https://www.ipsen.com/
The Effectiveness of Circadin in Improving Quality of Sleep in Patients Aged 55 or Over
- Conditions
- First Posted Date
- 2014-12-22
- Last Posted Date
- 2019-01-11
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 40
- Registration Number
- NCT02321449
- Locations
- 🇷🇺
State research center of preventive medicine, Moscow, Russian Federation
🇷🇺Research and Education Center of Moscow State University named after M.V. Lomonosov, Moscow, Russian Federation
🇷🇺First Moscow State Medical University, Moscow, Russian Federation
Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression
- Conditions
- Interventions
- First Posted Date
- 2014-12-22
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 42
- Registration Number
- NCT02321436
- Locations
- 🇲🇾
Neurology Laboratory -University Malaya Medical Centre, Kuala Lumpur, Malaysia
🇵🇭Center for Neurodiagnostic and Therapeutic Services Metropolitan Medical Center, Manila, Philippines
🇸🇬TTSH Rehabilitation Centre Ang Mo Kio Community Hospital, Singapore, Singapore
Efficacy, Safety and Tolerability of Eziclen in Adult Subjects Undergoing Colonoscopy
- First Posted Date
- 2014-12-22
- Last Posted Date
- 2019-03-04
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 296
- Registration Number
- NCT02321462
- Locations
- 🇷🇺
Federal State Budgetary Institution "State Scientifical Center of Coloproctology", Moscow, Russian Federation
🇷🇺State Healthcare Institution of Yaroslavl Region "Regional Clinical Cancer Hospital", Yaroslavl, Russian Federation
🇷🇺State Healthcare Institution Municipal Clinical Hospital No. 31 of Moscow, Moscow, Russian Federation
Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction
- First Posted Date
- 2014-10-27
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 52
- Registration Number
- NCT02275338
- Locations
- 🇧🇪
Ste-Elisabeth Hospital, Brussels, Belgium
ETREAT Study on Effectiveness of Botulinum Toxin Type A Injections to Treat Post-stroke Upper and/or Lower Limb Spasticity
- Conditions
- First Posted Date
- 2014-10-27
- Last Posted Date
- 2019-08-16
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 110
- Registration Number
- NCT02275312
Study To Assess Renewal Of Treatment In Patients Recently Diagnosed With Prostate Cancer
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2019-07-25
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 368
- Registration Number
- NCT02238366
Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients
- First Posted Date
- 2014-09-04
- Last Posted Date
- 2019-01-15
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 17
- Registration Number
- NCT02231580
Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET
- Conditions
- Interventions
- First Posted Date
- 2014-09-04
- Last Posted Date
- 2019-05-06
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 57
- Registration Number
- NCT02231762
- Locations
- 🇦🇹
Vienna General Hospital, Vienna, Austria
🇩🇪Charité University Hospital, Berlin, Germany
🇩🇪Zentralklinik Bad Berka, Bad Berka, Germany
SAGIT for Classification of Patients With Acromegaly in Clinical Practice
- First Posted Date
- 2014-09-04
- Last Posted Date
- 2020-03-31
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 71
- Registration Number
- NCT02231593
- Locations
- 🇫🇷
CHU Bicetre, Le Kremlin-Bicêtre, France
🇧🇷Federal University of Minas Gerais, Belo Horizonte, Brazil
🇧🇷Private practice, Saúde, Brazil
68Ga-OPS202 Study for Diagnostic Imaging of GEP NET
- Conditions
- Interventions
- First Posted Date
- 2014-06-12
- Last Posted Date
- 2019-10-02
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 12
- Registration Number
- NCT02162446
- Locations
- 🇨🇭
University Hospital Basel, Basel, Switzerland